Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748175 | 0.88 | DRD2 (0.36) | MAPTL3MBTL1KAT6AIDO1TDO2 | |
| SCHEMBL24353740 | 0.85 | MAPT (0.38) | MAPTL3MBTL1KAT6AIDO1TDO2 | |
| SCHEMBL23748274 | 0.83 | MAPT (0.49) | BRD4MAPTL3MBTL1CREBBPIDO1 | |
| SCHEMBL24353756 | 0.81 | MAPT (0.46) | BRD4MAPTL3MBTL1CREBBPCES2 | |
| SCHEMBL23748228 | 0.75 | IDO1 (0.35) | MAPTL3MBTL1KAT6AIDO1TDO2 | |
| SCHEMBL229877 | 0.74 | CES2 (0.45) | BRD4CES2CES1IGFBP3HDAC4 | |
| SCHEMBL23748221 | 0.74 | HTR2C (0.36) | KAT6AALDH1A1 | |
| SCHEMBL16213529 | 0.73 | MAPT (0.39) | MAPTL3MBTL1KAT6A | |
| SCHEMBL23748280 | 0.72 | CXCR5 (0.46) | MAPTIDO1TDO2ALDH1A1 | |
| SCHEMBL23748186 | 0.71 | MAPT (0.44) | MAPTL3MBTL1SLC6A9SLC6A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | ACE, PNP, FEN1 | BRD4 1584/4885MAPT 2999/4885L3MBTL1 2124/4885 |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | BRD4 1847/4885MAPT 3026/4885L3MBTL1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.